Errors in the ordering and interpretation of genetic tests for cancer, as well as in communicating results, are continuing to occur, and a newly published report highlighting some of these errors suggests that the nature of the mistakes are reflective of the rapid growth in the market — particularly with next-generation sequencing panels — and increasing consumer access through direct-to-consumer offerings.
- Looking Back on the 10-year Anniversary of the SCOTUS Decision
- Genetic Testing Challenges in Oncology: Karyotype, Germline Clues in Somatic Diagnosis Lost in Translation
- Genetic Testing Challenges in Oncology: Patient with Pending Bill has BRCA1 Result Withheld
- Precision Oncology in 2022: New Drugs and Tests Amid Ongoing Access Barriers
- NSGC 2022 Poster Presentation